I don't have a problem with the research trajectory of immuron or results or potential. I have a problem with the sales of its one and only product Travelan. This is an extraordinary product by any measure and the company is incapable of growing sales in any meaningful way up to this point. Maybe that will change but there is no evidence of it at this point. It appears they don't have the skills. This concerns me on other levels because it means they may lack the ability to drive the success of the overall enterprise.
I don't have a problem with the research trajectory of immuron...
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
10.0¢ |
Change
0.004(4.17%) |
Mkt cap ! $23.36M | |||
| Open | High | Low | Value | Volume |
| 10.5¢ | 10.5¢ | 10.0¢ | $18.03K | 176.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 244500 | 10.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 10.5¢ | 110313 | 7 |
View Market Depth
| Last trade - 12.45pm 16/08/2024 (20 minute delay) ? |
| IMC (ASX) Chart |